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Phorbol esters were employed in studies on the molecular mechanism of the induction of expression of hu- 
man T-cell leukemia virus type I (HTLV-I) by a tumor promoter, 12-O-tetradecanoylphorbol-13-acetate 
(TPA). Experiments using the chloramphenicol acetyltransferase (CAT) system showed that CAT expres- 
sion directed by the long terminal repeat (LTR) of HTLV-I was induced by TPA, but not by 4cc-phorbol- 
12,13_didecanoate, which is not an activator of protein kinase C, and that like other known enhancers, irre- 
spective of its position and orientation, a 230-bp fragment in the U3 region of the HTLV-I LTR confers 
susceptibility to induction by TPA. 
Enhancer; Gene expression; Long terminal repeat; Retrovirus; Tumor promoter 
1. INTRODUCTION 
Human T-cell leukemia virus type I appears to 
be the causative agent of adult T-cell leukemia and 
a member of the family of retroviruses [1,2]. 
Transcription from the LTR of HTLV-I is found 
only in cells containing a product of this virus, 
designated p40 [3-51, and the sequence in the LTR 
responsible for the p40-dependent induction is 
within an enhancer element in the U3 region [6-91. 
A tumor promoter, TPA, is known to induce the 
expression of viral antigens of HTLV-I [ 11, but the 
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molecular mechanism of this induction by TPA is 
unknown. In the present study, we found that 
TPA markedly activates gene expression directed 
by the LTR of HTLV-I and that the enhancer ele- 
ment in the U3 region mediates this activation. 
2. MATERIALS AND METHODS 
2.1. Cell lines 
The B cell lines LCL-Kan and ARH 77, the T 
cell line Jurkat, the monocyte line U937 and the 
erythroleukemia cell line K562 were used. These 
cell lines did not contain HTLV-I. TL-OmI is a T 
cell line that carries the HTLV-I proviral genome, 
but does not express any product of HTLV-I detec- 
table at the mRNA level or protein level [lO,ll]. 
2.2. DNA transfection 
Plasmid DNAs (1Opg) were transfected into cells 
(5 x 106) by the DEAE-dextran method [9,12]. 
The transfected cells were cultured in RPM1 1640 
medium containing 20% fetal calf serum for 12 h 
and then cultured for 24 h in the presence or 
absence of TPA (5 ng/ml). 
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2.3. CAT assay 
The CAT activity was determined as described in 
[9,13]. Cell extracts prepared by the freeze-thaw 
method were incubated for 1 h in 150~1 of reaction 
mixture containing 0.5 mM acetyl CoA and 0.1 ,uCi 
[‘4C]chloramphenicol (54 mCi/mmol, Amersham, 
Bucks, England). Chloramphenicol and its 
derivatives were extracted with ethyl acetate and 
analyzed on silica gel thin layer plates (Merck, 
Darmstadt, FRG) in 95% chloroform:5% me- 
thanol. Then the plates were autoradiographed 
and the radioactivity of the spots was counted. The 
CAT activity was expressed as the percentage of 
[14C]chloramphenicol converted to acetylated 
forms. 
3. RESULTS 
To study the mechanism of induction of HTLV- 
I by TPA, we examined the effect of TPA on ex- 
pression of the CAT gene under the control of the 
HTLV-I LTR. For this, we first tested various 
hematopoietic ell lines for use in the CAT assay. 
A plasmid pCHL4 (fig.3A), which contains the 
LTR-directed CAT gene [9], was transfected into 
cells and 12 h later TPA was added. TPA treat- 
ment increased CAT activity in all the cell lines 
tested, the increase in the K562 cell line being 
greatest (table 1). Therefore, K562 cells were used 
Table 1 
Effects of TPA on gene xpression driven by the HTLV- 
I promoter unit in various cell lines 
CAT activity 
Vo conversion 
Cell line - TPA + TPA Index 
Jurkat 1.8 5.5 3.1 
TL-OmI 0.2 0.5 2.5 
LCL-Kan 0.4 1.3 3.3 
ARH77 18.5 60.3 3.3 
u937 0.9 3.4 3.8 
K562 0.5 43.1 86.2 
pCHL4 was transfected into cells (5 x 106) and after 12 
h, TPA was added at a concentration of 5 ng/ml, and 
cells were cultured for a further 24 h. CAT activity in the 
extract was assayed and is shown as the percent conver- 
sion. The index represents the ratio of the CAT activities 
in the presence and absence of TPA 
300 
in subsequent experiments. The specificity of phor- 
bol esters was examined by comparing TPA effect 
with that of 4cu-PDD, which does not induce viral 
expression or activate protein kinase C. The CAT 
activity from pCHL4 was increased 96-fold by 
treatment with TPA, but was not increased by &- 
PDD (fig.1). 
The effects of TPA on several other viral 
transcriptional units were also examined. Increase 
in CAT activity on addition of TPA was 
demonstrated with a CAT construct (pRSVcat) 
containing the promoter unit of Rous sarcoma 
virus. Plasmids containing the SV40 (pSEHL4) 
and polyoma virus (pWEN . CAT) enhancers 
showed similar significant increases in activity on 
TPA treatment as reported in [14,15]. Slight in- 
crease was observed with a plasmid (pMEHL4) 
containing the murine sarcoma virus (MSV) 
enhancer (fig.2). 
We have reported that two regulatory elements 
in the HTLV-I LTR, a 230-bp enhancer element in 
the U3 region and a 300-bp element in the R 
region, are responsible for maximum gene expres- 
sion [9]. We thus addressed the question of which 
element was affected by TPA. CAT plasmids con- 
taining the two elements in different positions and 
orientations were tested for responsiveness to TPA 
(fig.3A). The CAT activity of the enhancerless 
pSV1Ccat was not affected by TPA, but the CAT 
activities of plasmidwntaining the U3 enhancer 
element were increased 20-50-fold irrespective of 
the position and orientation of the fragment 
(fig.3B). The activity of pdERH-1 containing the R 
region was increased only 2-fold by TPA. These 
Treatment 
CAT Activity 
%Conversion (Index) 
None 0.8 
TPA (5nglml) 76.0 (96.0) 
&-PDD (5ng/ml) 0.9 (1.1) 
4,1-PDD (SOnglml) 0.5 (0.6) 
Fig. 1. The absence of effect of 4~PDD on the promoter 
unit of HTLV-I LTR. K562 cells were transfected with 
pCHL4 and 12 h later TPA or 4~PDD was added at the 
indicated concentrations. The CAT activity in cell ex- 
tracts was assayed. The percentage conversion and the 
index described as in the legend of table 1 are shown. 
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Fig.2. Effect of TPA on several viral promoter units. CAT constructs containing enhancer-promoter units from SV40, 
RSV, MSV and polyoma virus were introduced into K562 cells. TPA was added at a concentration of 5 ng/ml 12 h 
after transfection. The CAT assay and the presentation of data are as described in the legend of table 1. 
data strongly indicate that the enhancer element in _- 
the U3 region of the HTLV-I LTR mediates induc- 
tion of gene expression from the LTR by TPA. 
4. DISCUSSION 
We demonstrated that a 230-bp fragment in the 
U3 region mediates activation by TPA of gene ex- 
pression directed by the HTLV-I LTR in the cell 
lines tested. K562 cells showed a greatly enhanced 
activity on treatment with TPA. We do not know 
why their response differed quantitatively from 
those of other cells, but it might be due to abnor- 
mal expression of a protooncogene c-abl in K562 
cells [16]. The domain responsible for TPA 
enhancement appeared to be a TPA-inducible 
enhancer, indicating that the TPA-inducible 
enhancement occurs at a transcriptional evel and 
that there is a cellular factor that interacts with the 
enhancer element in the 230-bp fragment. The in- 
teraction may result in the enhancement of gene 
expression. The mechanisms involved in the activa- 
tion of the HTLV-I enhancer by TPA are not 
understood. It is, however, likely that TPA 
modulates the so-called trans-acting transcrip- 
tional factor(s). TPA may induce expression of the 
factor(s), or alternatively may convert it from an 
inactive to an active state. Protein kinase C may be 
involved in this modulation of the factor(s), since 
the activation was observed with TPA, but not 
with ICY-PDD, which does not activate protein 
kinase C. TPA is known to activate enhancers of 
SV40 and polyoma virus in a similar manner, ap- 
parently modifying the trans-acting factor post- 
transcriptionally [ 14,151. 
~40, a product of the pX region of HTLV-I, 
trans-activates gene expression directed by its own 
LTR, and the 21-bp motif in the U3 region of the 
LTR has been shown to be responsible for this 
p40-induced activation [8]. An intriguing question 
is whether the 21-bp motif can also confer TPA in- 
ducibility. Our preliminary results suggested that 
this is not the case. These observations suggested 
that multiple elements in the enhancer are involved 
in activation of gene expression of HTLV-I. The 
consensus equences responsible for TPA respon- 
siveness, ;TGACT;A and CTGACTCA, have 
301 
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Fig.3. (A) Schematic representation of CAT constructs. Details of the constructions of these plasmids have been describ- 
ed [9]. (B) Ability of the enhancer fragment of HTLV-I to confer TPA-dependent activation. Each plasmid (10pg) was 
transfected into KS62 cells and 12 h later TPA (5 ng/ml) was added. Conditions for the CAT assay and representation 
of data are as described in the legend of table 1. 
very recently been reported [17,18]. Although we 
found, in the previous study, that a pen- 
tanucleotide, CTGAC, which is also included in 
the TPA-consensus sequences, is present in severa 
enhancers including the 230-bp enhancer of the 
HTLV-I LTR [Saito, S. et al., submitted], the 
HTLV-I enhancer does not contain the sequence 
Our results also suggested that the mechanism of 
enhancement of gene expression by TPA could be 
different from that by ~40. This notion indicates 
the possibility that, even in the absence of ~40, ex- 
pression of HTLV-I genes including pX genes may 
be induced by exogenous stimuli. This possibility 
could explain the initial step of expression and 
entirely homologous to the consensus sequences. 
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replication of this virus. 
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